Cargando…

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

With the potential development of new disease-modifying Alzheimer’s Disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals who are experiencing symptoms of cognitive or behavioral decline should be further evaluated for initiation of treatment. A bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thijssen, Elisabeth H., La Joie, Renaud, Wolf, Amy, Strom, Amelia, Wang, Ping, Iaccarino, Leonardo, Bourakova, Viktoriya, Cobigo, Yann, Heuer, Hilary, Spina, Salvatore, VandeVrede, Lawren, Chai, Xiyun, Proctor, Nicholas K., Airey, David C., Shcherbinin, Sergey, Evans, Cynthia Duggan, Sims, John R., Zetterberg, Henrik, Blennow, Kaj, Karydas, Anna M., Teunissen, Charlotte E., Kramer, Joel H., Grinberg, Lea T., Seeley, William W., Rosen, Howie, Boeve, Bradley F., Miller, Bruce L., Rabinovici, Gil D., Dage, Jeffrey L., Rojas, Julio C., Boxer, Adam L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101073/ https://www.ncbi.nlm.nih.gov/pubmed/32123386 http://dx.doi.org/10.1038/s41591-020-0762-2

Ejemplares similares

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
por: VandeVrede, Lawren, et al.
Publicado: (2023)

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023)

Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
por: Samudra, Niyatee, et al.
Publicado: (2023)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2022)

Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration
por: Asken, Breton M, et al.
Publicado: (2023)

Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS
por: Rosen, Howard J., et al.
Publicado: (2020)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome
por: Asken, Breton M., et al.
Publicado: (2023)

A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques
por: Moreno, Fermin, et al.
Publicado: (2015)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
por: Siklos, Marton I, et al.
Publicado: (2013)

Rates of lobar atrophy in asymptomatic MAPT mutation carriers
por: Chen, Qin, et al.
Publicado: (2019)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

The role of neurofilament light in genetic frontotemporal lobar degeneration
por: Zetterberg, Henrik, et al.
Publicado: (2022)

An NO Donor Approach to Neuroprotective and Procognitive Estrogen Therapy Overcomes Loss of NO Synthase Function and Potentially Thrombotic Risk
por: VandeVrede, Lawren, et al.
Publicado: (2013)

Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers
por: Chen, Qin, et al.
Publicado: (2019)

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
por: Berry, Kacey, et al.
Publicado: (2022)

Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning
por: Scotton, William J, et al.
Publicado: (2023)

Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
por: Ljubenkov, Peter A., et al.
Publicado: (2018)

NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
por: Thatcher, Gregory RJ, et al.
Publicado: (2013)

Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling
por: Cobigo, Yann, et al.
Publicado: (2022)

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
por: Horie, Kanta, et al.
Publicado: (2022)

Frequency specific contribution of intrinsic connectivity networks to the integration in brain networks
por: Park, Yeong-Hun, et al.
Publicado: (2019)

Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease
por: Garbutt, Siobhan, et al.
Publicado: (2008)

Preferential tau aggregation in von Economo neurons and fork cells in frontotemporal lobar degeneration with specific MAPT variants
por: Lin, Li-Chun, et al.
Publicado: (2019)

Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
por: Windon, Charles, et al.
Publicado: (2022)

Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia
por: Luo, Jia, et al.
Publicado: (2015)

Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy
por: Lesman-Segev, Orit H, et al.
Publicado: (2019)

Risk Factors for Lobar and Non-Lobar Intracerebral Hemorrhage in Patients with Vascular Disease
por: Kremer, Philip H. C., et al.
Publicado: (2015)

A data-driven model of brain volume changes in progressive supranuclear palsy
por: Scotton, W. J., et al.
Publicado: (2022)

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
por: Rojas, Julio C., et al.
Publicado: (2021)

Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
por: Olney, Nicholas T., et al.
Publicado: (2020)

Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration
por: Staffaroni, Adam M., et al.
Publicado: (2020)

TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration
por: Buciuc, Marina, et al.
Publicado: (2022)

Retinal imaging demonstrates reduced capillary density in clinically unimpaired APOE ε4 gene carriers
por: Elahi, Fanny M., et al.
Publicado: (2021)

Lobar Pneumonia
por: Liles, J. P.
Publicado: (1912)

Data‐driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration
por: Binney, Richard J., et al.
Publicado: (2017)

Delusions in frontotemporal lobar degeneration
por: Omar, Rohani, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_q69sq8n8ho9jhjodt49l3miufg